• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Contemporary Issues in Urothelial Carcinoma of Upper Urinary Tract.上尿路尿路上皮癌的当代问题
Adv Anat Pathol. 2024 Mar 1;31(2):80-87. doi: 10.1097/PAP.0000000000000421. Epub 2023 Nov 27.
2
Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma.上尿路尿路上皮癌临床病理特征的预测中,上尿路细胞学和活检的临床实用性和一致性。
Hum Pathol. 2019 Apr;86:76-84. doi: 10.1016/j.humpath.2018.11.021. Epub 2018 Dec 8.
3
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.欧洲泌尿外科学会上尿路上皮细胞癌指南:2015 年更新版。
Eur Urol. 2015 Nov;68(5):868-79. doi: 10.1016/j.eururo.2015.06.044. Epub 2015 Jul 16.
4
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update.欧洲泌尿外科学会上尿路尿路上皮癌指南:2020 年更新版。
Eur Urol. 2021 Jan;79(1):62-79. doi: 10.1016/j.eururo.2020.05.042. Epub 2020 Jun 24.
5
Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.非肌层浸润性膀胱肿瘤史对上尿路尿路上皮癌患者的预后意义。
Urol Oncol. 2013 Nov;31(8):1615-20. doi: 10.1016/j.urolonc.2012.03.004. Epub 2012 Apr 21.
6
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.欧洲泌尿外科学会上尿路尿路上皮癌指南:2023 年更新版。
Eur Urol. 2023 Jul;84(1):49-64. doi: 10.1016/j.eururo.2023.03.013. Epub 2023 Mar 24.
7
Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma.多机构验证术前积水在预测上尿路上皮癌高级别病理肿瘤分期中的能力。
Urol Oncol. 2013 Aug;31(6):904-8. doi: 10.1016/j.urolonc.2011.07.011. Epub 2011 Sep 9.
8
Prognostic Impact of pT3 Subclassification in a Multicentre Cohort of Patients with Urothelial Carcinoma of the Renal Pelvicalyceal System Undergoing Radical Nephroureterectomy: A Propensity Score-weighted Analysis After Central Pathology Review.多中心队列研究中经中心病理审查后采用倾向评分加权分析对接受根治性肾输尿管切除术的肾盂输尿管系统尿路上皮癌患者 pT3 亚分类的预后影响。
Eur Urol Focus. 2021 Sep;7(5):1075-1083. doi: 10.1016/j.euf.2020.10.004. Epub 2020 Oct 24.
9
International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis.国际验证 AJCC 分期 pT3 肾盂上尿路上皮癌亚分类的预后价值。
BJU Int. 2012 Sep;110(5):674-81. doi: 10.1111/j.1464-410X.2012.10930.x. Epub 2012 Feb 20.
10
Oncologic outcomes of patients treated with kidney-sparing surgery or radical nephroureterectomy for upper urinary tract urothelial cancer: a population-based study.保留肾单位手术或根治性肾输尿管切除术治疗上尿路尿路上皮癌患者的肿瘤学结局:一项基于人群的研究。
Urol Oncol. 2024 Jan;42(1):22.e1-22.e11. doi: 10.1016/j.urolonc.2023.09.019. Epub 2023 Nov 18.

本文引用的文献

1
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.欧洲泌尿外科学会上尿路尿路上皮癌指南:2023 年更新版。
Eur Urol. 2023 Jul;84(1):49-64. doi: 10.1016/j.eururo.2023.03.013. Epub 2023 Mar 24.
2
Renal Pelvic Urothelial Carcinoma With Invasion Into Renal Medulla Can Be Redefined as pT2 to Improve Correlation With Survival.肾髓质浸润性肾盂尿路上皮癌可重新定义为 pT2,以提高与生存的相关性。
Mod Pathol. 2023 Jun;36(6):100140. doi: 10.1016/j.modpat.2023.100140. Epub 2023 Feb 20.
3
Subclassification of pT3 upper tract urothelial carcinoma: a multicenter retrospective study.pT3 上尿路尿路上皮癌的亚分类:一项多中心回顾性研究
World J Urol. 2023 Mar;41(3):767-776. doi: 10.1007/s00345-023-04300-7. Epub 2023 Feb 4.
4
Nested Subtype of Urothelial Carcinoma in the Upper Urinary Tract: A Series of 15 Cases.上尿路尿路上皮癌的嵌套亚型:15例病例系列
Am J Surg Pathol. 2023 Apr 1;47(4):461-468. doi: 10.1097/PAS.0000000000002008. Epub 2022 Dec 19.
5
Cancer statistics, 2023.癌症统计数据,2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
6
Molecular uropathology and cancer genetics for the urologist: key findings for classification and diagnosis.分子泌尿病理学和癌症遗传学:泌尿外科医生的关键发现用于分类和诊断。
Curr Opin Urol. 2022 Sep 1;32(5):451-455. doi: 10.1097/MOU.0000000000001025. Epub 2022 Jul 18.
7
Reclassifying pT3 renal pelvic urothelial carcinoma with renal parenchyma invasion to pT2 improves correlation with overall survival.将肾盏壁有肾实质侵犯的 pT3 肾盂尿路上皮癌重新分类为 pT2 可提高与总生存的相关性。
Hum Pathol. 2022 Jul;125:79-86. doi: 10.1016/j.humpath.2022.03.004. Epub 2022 Mar 17.
8
Immunohistochemical Screening of Upper Tract Urothelial Carcinomas for Lynch Syndrome Diagnostics: A Systematic Review.免疫组织化学在上尿路尿路上皮癌中筛选林奇综合征的诊断:系统评价。
Urology. 2022 Jul;165:44-53. doi: 10.1016/j.urology.2022.02.006. Epub 2022 Feb 22.
9
Upper Urinary Tract Urothelial Carcinoma in Lynch Syndrome Patients: The Urologist Still Has a Role in Genetic Screening.林奇综合征患者的上尿路尿路上皮癌:泌尿外科医生在基因筛查中仍发挥作用。
Eur Urol Oncol. 2022 Feb;5(1):42-43. doi: 10.1016/j.euo.2021.12.004. Epub 2021 Dec 31.
10
Lynch syndrome in urological practice: diagnosis, therapeutic strategies, and screening for upper tract urothelial carcinoma.泌尿外科临床中的林奇综合征:诊断、治疗策略及上尿路尿路上皮癌的筛查
Curr Opin Urol. 2022 Jan 1;32(1):40-47. doi: 10.1097/MOU.0000000000000936.

上尿路尿路上皮癌的当代问题

Contemporary Issues in Urothelial Carcinoma of Upper Urinary Tract.

作者信息

Zhao Jianping, Guo Charles C, Rao Priya

机构信息

Department of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.

出版信息

Adv Anat Pathol. 2024 Mar 1;31(2):80-87. doi: 10.1097/PAP.0000000000000421. Epub 2023 Nov 27.

DOI:10.1097/PAP.0000000000000421
PMID:38009077
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10922730/
Abstract

Upper urinary tract urothelial carcinoma (UTUC) is an uncommon malignancy involving the renal pelvis and ureter. Careful pathologic analysis plays a critical role in the diagnosis and clinical management of UTUC. In combination with clinical and radiologic evaluation, pathologic features can be used to stratify patients into low-risk and high-risk groups. This risk stratification can help clinicians select the optimal treatment for patients with UTUC, such as kidney-sparing (conservative) treatment, radical nephroureterectomy or ureterectomy, and perioperative systemic therapy. However, due to the technical difficulty of obtaining sufficient tissue from the upper urinary tract, it is often challenging for pathologists to accurately grade the tumor and assess tumor invasion in small biopsy specimens. Although the majority of UTUCs are pure urothelial carcinoma, a considerable subset of UTUCs show histologic subtypes or divergent differentiation. Recent studies have identified genetically distinct molecular subtypes of UTUC by examining DNA, RNA, and protein expression profiles. The prognosis of pT3 UTUC, particularly renal pelvic UC, remains controversial, and several studies have proposed subclassification of pT3 UTUC. Lynch syndrome is a significant risk factor for UTUC, and screening tests may be considered in young patients and those with familial histories of the disease. Despite significant progress in recent years, several issues remain to be addressed in the pathologic diagnosis, molecular classification, and treatment of UTUC.

摘要

上尿路尿路上皮癌(UTUC)是一种累及肾盂和输尿管的罕见恶性肿瘤。仔细的病理分析在UTUC的诊断和临床管理中起着关键作用。结合临床和影像学评估,病理特征可用于将患者分为低风险和高风险组。这种风险分层有助于临床医生为UTUC患者选择最佳治疗方案,如保留肾(保守)治疗、根治性肾输尿管切除术或输尿管切除术以及围手术期全身治疗。然而,由于从上尿路获取足够组织存在技术困难,病理学家在小活检标本中准确分级肿瘤和评估肿瘤浸润往往具有挑战性。虽然大多数UTUC是单纯尿路上皮癌,但相当一部分UTUC表现出组织学亚型或异向分化。最近的研究通过检查DNA、RNA和蛋白质表达谱确定了UTUC的基因不同分子亚型。pT3 UTUC,尤其是肾盂UC的预后仍存在争议,一些研究提出了pT3 UTUC的亚分类。林奇综合征是UTUC的一个重要危险因素,对于年轻患者和有该病家族史的患者可考虑进行筛查试验。尽管近年来取得了重大进展,但在UTUC的病理诊断、分子分类和治疗方面仍有几个问题有待解决。